University Of Notre Dame Du Lac Insmed Inc Transaction History

University Of Notre Dame Du Lac

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$16.12 - $24.98 $926,448 - $1.44 Million	-57,472 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$15.49 - $25.78 $890,241 - $1.48 Million	57,472 New	57,472 $1.01 Million
Q2 2019 Aug 14, 2019	SELL	$23.0 - $32.19 $2.28 Million - $3.18 Million	-98,939 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$13.91 - $31.15 $502,498 - $1.13 Million	-36,125 Reduced 26.75%	98,939 $2.88 Million
Q4 2018 Feb 13, 2019	BUY	$11.6 - $18.7 $32,990 - $53,182	2,844 Added 2.15%	135,064 $1.77 Million
Q3 2018 Nov 13, 2018	BUY	$18.95 - $28.08 $590,425 - $874,888	31,157 Added 30.83%	132,220 $2.67 Million
Q2 2018 Aug 14, 2018	BUY	$20.0 - $29.72 $206,200 - $306,413	10,310 Added 11.36%	101,063 $2.39 Million
Q1 2018 May 15, 2018	BUY	$21.69 - $32.99 $78,778 - $119,819	3,632 Added 4.17%	90,753 $2.04 Million
Q4 2017 Feb 13, 2018	SELL	$26.43 - $31.78 $3.05 Million - $3.66 Million	-115,292 Reduced 56.96%	87,121 $2.72 Million
Q3 2017 Nov 13, 2017	BUY	$11.61 - $31.21 $2.35 Million - $6.32 Million	202,413	202,413 $6.32 Million

484

187M

2.15M

3.22M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.7B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of University Of Notre Dame Du Lac, based on Form 13F filings with the SEC.

Stay updated on University Of Notre Dame Du Lac with notifications on news.